Forbes December 23, 2024
Rita Numerof

Global cost pressures and a fast-changing political and regulatory landscape indicate that the pharmaceutical industry is at an inflection point as we head into 2025, as we outline in our recently published Numerof & Associates 2025 Global Pharma Outlook.

To navigate this increasingly complex environment, manufacturers must fundamentally rethink their models, focusing on long-term value, evidence-based decision-making and strategic collaboration.

At a macro level, the single biggest factor in the current landscape is continuing pressure from both government and private payers to reduce the cost and ensure the value of drugs. Across the globe, government payers are raising the bar for market entry. This takes the form of increasing evidentiary requirements and growing complexity in rules that govern reimbursement.

This...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma, Pharma / Biotech
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
Why Walgreens Is Reportedly Considering a Private Equity Buyer
Why 2025 Could Be A Good Reimbursement Year For CVS And Walgreens
PBM reform dropped in Congress' funding package

Share This Article